New Study Finds PEPITEM Peptide Reduces Joint Swelling in Arthritis Models

A study published in the journal Arthritis and Rheumatology reports that the peptide PEPITEM reduced joint swelling in animal models of inflammatory arthritis to a degree comparable to a current standard treatment. The research, conducted by scientists from the University of Birmingham and the University of Federico III, Naples, also found the treatment resulted in less joint inflammation, cartilage damage, and bone erosion in mice.

Research Background and Mechanism

PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) is a peptide first identified by University of Birmingham researchers. It is part of a biological pathway involving the hormone adiponectin, which helps regulate the movement of immune cells.

• In conditions like rheumatoid arthritis and psoriatic arthritis, white blood cells in the joints do not respond properly to adiponectin and secrete less PEPITEM.
• Researchers state this reduction impairs a natural mechanism that limits white blood cell migration into joint cavities, contributing to inflammation.

Key Findings from the Study

The investigation involved both human cell studies and animal models.

• Analysis of blood cells from treatment-naïve human donors with suspected inflammatory arthritis showed a reduced capacity to respond to adiponectin.
• Adding PEPITEM restored this response in the cells.
• Examination of whole blood indicated lower levels of bioavailable PEPITEM in patients with early rheumatoid arthritis.

• In mouse models of inflammatory arthritis, injection of synthetic PEPITEM prevented the onset of disease and reduced its incidence.
• The treatment reduced joint swelling to an extent described as comparable to the drug infliximab, a current standard treatment.
• Tissue analysis showed PEPITEM-treated mice had less joint inflammation, cartilage damage, and bone erosion, with fewer white blood cells infiltrating the joints.
• Molecular studies indicated the treatment downregulated inflammatory mediators (NF-kB and COX2 protein) and increased the expression of foxp3 transcript in synovial tissue, which is involved in immune regulation.

Researcher Statements and Potential Implications

Professor Helen McGettrick of the University of Birmingham, who led the study, provided statements on the findings.

"The research showed observable reversal of clinical disease manifestation in the models and that PEPITEM has the potential to provide an alternative therapy to limit disease severity and progression in early-stage inflammatory arthritis."

• McGettrick noted potential benefits could include a lower toxicity risk compared to some existing immunosuppressive therapies and a possible reduction in early reliance on steroid treatments.
• The researcher added that existing Disease-Modifying Anti-Rheumatic Drugs (DMARDs) do not reverse joint damage even when inflammation is controlled.
• Previous research by the team has indicated PEPITEM may also have therapeutic potential for bone repair by enhancing bone mineralization and strength.

The study notes that the research examined inflammatory arthritis models in Birmingham and gouty arthritis models in Naples.